Energenesis Biomedical Co., Ltd. (TWSE: 6657) is preparing to showcase promising developments in its investigational Parkinson's disease therapy ENERGI-F705PD at the BIO International Convention 2025 in Boston, with Phase I data expected in September 2025. The clinical-stage biotechnology company announced its participation in the conference taking place June 16-19, where it will present updates on the first-in-class treatment designed to address underlying disease pathogenesis.
Novel Mechanism Targets Disease Hallmarks
ENERGI-F705PD represents a novel approach to Parkinson's disease treatment through its oral sustained-release formulation that enhances cellular ATP and antioxidant production. The therapy engages multiple metabolic pathways including purine salvage, glycolysis, and pentose phosphate pathways to address key pathological hallmarks of the neurodegenerative condition.
The multi-pronged mechanism of action specifically targets three critical aspects of Parkinson's disease pathology. The therapy aims to reduce and prevent α-synuclein aggregation by utilizing elevated ATP as a hydrotrope to prevent intracellular aggregation of misfolded α-synuclein, a central pathogenic hallmark of the disease. Additionally, ENERGI-F705PD upregulates the pentose phosphate pathway, leading to increased NADPH production and enhanced cellular antioxidant defense systems.
Dopamine Synthesis Enhancement
The therapy also addresses neurotransmitter deficiency by enhancing tyrosine hydroxylase expression and activity. By optimizing cellular energy metabolism and engaging the purine salvage pathway, ENERGI-F705PD enhances the expression and activity of tyrosine hydroxylase, the key enzyme in dopamine synthesis, thereby helping restore neurotransmitter levels in the brains of Parkinson's disease patients.
"Parkinson's disease remains a challenging condition with significant unmet needs," said Dr. Han-Min Chen, CEO of Energenesis Biomedical. "Our approach focuses on restoring cellular energy and combating critical pathogenesis of PD, offering a potential disease-modifying solution for patients."
Clinical Development Timeline
The company has successfully completed recruitment for its Phase I trial in healthy subjects, with topline data anticipated in September 2025. This milestone represents a critical step in the development of what the company describes as a first-in-class treatment with disease-modifying potential.
Broader Pipeline Context
ENERGI-F705PD is part of Energenesis Biomedical's broader therapeutic pipeline focused on cellular energy restoration. The company's portfolio includes ENERGI-F703DFU gel for diabetic foot ulcers currently in Phase III, ENERGI-F701 tonic for alopecia with completed Phase II trials, and ENERGI-F703EB cream for epidermolysis bullosa, which has received FDA Orphan Drug and Rare Pediatric Disease designation as well as EMA orphan designation.
The company will be located at Booth #1645 within the Taiwan Pavilion at BIO International 2025, where it plans to explore potential partnerships to accelerate development of the Parkinson's disease therapy.
